221 related articles for article (PubMed ID: 36016434)
1. The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients.
Tseng CW; Liu WC; Ko PH; Chen YC; Tseng KC; Chang TT
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016434
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
Yeh ML; Huang CF; Huang CI; Holmes JA; Hsieh MH; Tsai YS; Liang PC; Tsai PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chung RT; Yu ML
J Hepatol; 2020 Jul; 73(1):62-71. PubMed ID: 32061869
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B Reactivation in Patients Treated with Direct-Acting Antivirals for Hepatitis C.
Toka B; Köksal AŞ; Dertli R; Şirin G; Fidan S; Ülger Y; Harmandar F; Yıldırım AE; Eminler AT; Asil M; Kayar Y; Bıyık M; Kuran S; Uslan MI; Hülagü S
Dig Dis; 2022; 40(5):635-643. PubMed ID: 35108715
[TBL] [Abstract][Full Text] [Related]
4. Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort.
Serper M; Forde KA; Kaplan DE
J Viral Hepat; 2018 Feb; 25(2):187-197. PubMed ID: 28845882
[TBL] [Abstract][Full Text] [Related]
5. HBV reactivation during direct-acting antiviral therapy in hepatitis B and C coinfected patients undergoing haemodialysis.
Wang J; Hu C; Chen Y; Liu Z; Yu Q; Yang S; Dong J; Yang Y; Wu Y; Ren D; Yao N; Guo D; Tian Z; Zhao Y; Chen T; He Y; Liu J
Antivir Ther; 2019; 24(2):77-84. PubMed ID: 30833515
[TBL] [Abstract][Full Text] [Related]
6. Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV.
Tseng CW; Liu WC; Chen CY; Chang TT; Tseng KC
BMC Infect Dis; 2022 Apr; 22(1):351. PubMed ID: 35397497
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B Reactivation Following Eradication of HCV with Direct-Acting Antiviral Drugs (DAAs) in a Cohort of Patients from Different Institutions in Egypt.
Abdelbary MS; Samir R; El-Nahaas SM; Shahin RMH; El-Sayed M; Gaber Y; Tantawi O; Zayed NA; Yosry A
J Clin Exp Hepatol; 2022; 12(5):1276-1284. PubMed ID: 36157140
[TBL] [Abstract][Full Text] [Related]
8. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
[TBL] [Abstract][Full Text] [Related]
10. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort.
Mücke VT; Mücke MM; Peiffer KH; Weiler N; Welzel TM; Sarrazin C; Zeuzem S; Berger A; Vermehren J
Aliment Pharmacol Ther; 2017 Aug; 46(4):432-439. PubMed ID: 28627791
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis.
Jiang XW; Ye JZ; Li YT; Li LJ
World J Gastroenterol; 2018 Jul; 24(28):3181-3191. PubMed ID: 30065564
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus coinfection in patients treated for chronic hepatitis C: clinical characteristics, risk of reactivation with long-term follow-up, and effectiveness of antiviral therapy.
Zarębska-Michaluk D; Brzdęk M; Rzymski P; Dobrowolska K; Flisiak R
Pol Arch Intern Med; 2024 Jan; 134(1):. PubMed ID: 38164525
[TBL] [Abstract][Full Text] [Related]
13. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data.
El Kassas M; Shimakawa Y; Ali-Eldin Z; Funk AL; Wifi MN; Zaky S; El-Raey F; Esmat G; Fontanet A
Liver Int; 2018 Dec; 38(12):2159-2169. PubMed ID: 29738637
[TBL] [Abstract][Full Text] [Related]
14. Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy.
Majeed NA; Alawad AS; Liem KS; Takyar V; Alter H; Feld JJ; Janssen HLA; Ghany MG
Dig Dis Sci; 2023 Jul; 68(7):3193-3198. PubMed ID: 37022602
[TBL] [Abstract][Full Text] [Related]
15. Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas.
Lan TY; Lin YC; Tseng TC; Yang HC; Kao JH; Cheng CF; Lee TJ; Huang SC; Lu CH; Li KJ; Hsieh SC
Gut Liver; 2023 Mar; 17(2):288-298. PubMed ID: 36268584
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection.
Jacob R; Danta M
Expert Opin Pharmacother; 2022 Mar; 23(4):465-472. PubMed ID: 34937470
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
Bersoff-Matcha SJ; Cao K; Jason M; Ajao A; Jones SC; Meyer T; Brinker A
Ann Intern Med; 2017 Jun; 166(11):792-798. PubMed ID: 28437794
[TBL] [Abstract][Full Text] [Related]
18. The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy.
Stroffolini T; Sagnelli E; Sagnelli C; Smedile A; Furlan C; Morisco F; Coppola N; Andriulli A; Almasio PL
Dig Liver Dis; 2019 Mar; 51(3):434-437. PubMed ID: 30361062
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
[TBL] [Abstract][Full Text] [Related]
20. Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial.
Cheng PN; Liu CJ; Chen CY; Tseng KC; Lo CC; Peng CY; Lin CL; Chiu HC; Chiu YC; Chen PJ
Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2800-2808. PubMed ID: 34864158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
